Cowen & Company Downgrades Ironwood Pharmaceuticals To Market Perform

Analysts at Cowen & Company downgraded Ironwood Pharmaceuticals

from Outperform to Market Perform. The target price for Ironwood Pharmaceuticals has been lowered from $16 to $10.50. Ironwood shares have gained 4.25% over the past 52 weeks, while the S&P 500 index has jumped 20.88% in the same period. Ironwood Pharmaceuticals' shares fell 0.92% to close at $12.99 yesterday.